Skip to main content

Table 1 Correlation between TBX21 expression and different clinical characteristics in LUAD patients enrolled in the study

From: TBX21 predicts prognosis of patients and drives cancer stem cell maintenance via the TBX21–IL-4 pathway in lung adenocarcinoma

Variable

Low TBX21 expression group

HighTBX21 expression group

P value#

GSE50081

 Stage

  

0.385

  I

37 (78.7%)

45 (71.4%)

 

  ≥ II

10 (21.3%)

18 (28.6%)

 Age

  

0.245

  < 65 years

14 (26.4%)

23 (36.5%)

 

  ≥ 65 years

39 (73.6%)

40 (63.5%)

 Gender

  

0.877

  Female

26 (49.1%)

30 (47.6%)

 

  Male

27 (50.9%)

33 (52.4%)

 Smoking

  

0.364

  No

11 (20.8%)

9 (14.3%)

 

  Yes

35 (66.0%)

49 (77.8%)

  NA

7 (13.2%)

5 (7.9%)

GSE31210

 Stage

  

0.296

  I

74 (78.7%)

45 (71.4%)

 

  ≥ II

20 (21.3%)

18 (28.6%)

 Age

  

0.107

  < 65 years

71 (74.0%)

39 (61.9%)

 

  ≥ 65 years

25 (26.0%)

24 (38.1%)

 Gender

  

0.382

  Female

51 (53.1%)

29 (46.0%)

 

  Male

45 (46.9%)

34 (54.0%)

 Smoking

  

0.419

  No

52 (54.2%)

30 (47.6%)

 

  Yes

44 (45.8%)

33 (52.4%)

GSE30219

 Stage

  

0.801

  I

27 (87.1%)

34 (85%)

 

  ≥ II

4 (12.9%)

6 (15%)

 Age

  

0.583

  < 65 years

19 (73.1%)

26 (66.7%)

 

  ≥ 65 years

7 (26.9%)

13 (33.3%)

 Gender

  

0.376

  Female

9 (29.0%)

8 (20.0%)

 

  Male

22 (71.0%)

32 (80.0%)

GSE68465

 Stage

  

0.448

  I

62 (36.3%)

55 (32.4%)

 

  ≥ II

109 (63.7%)

115 (67.6%)

 Age

  

0.746

  < 65 years

85 (49.7%)

82 (48.0%)

 

  ≥ 65 years

86 (50.3%)

89 (52.0%)

 Gender

  

0.175

  Female

81 (47.4%)

93 (54.7%)

 

  Male

90 (52.6%)

77 (45.3%)

 Smoking

  

0.105

  No

19 (11.1%)

22 (12.9%)

 

  Yes

108 (63.2%)

121 (70.8%)

  NA

44 (25.7%)

28 (16.3%)

GSE72094

 Stage

  

0.570

  I

99 (63.5%)

88 (66.7%)

 

  ≥ II

57 (36.5%)

44 (33.3%)

 Age

  

0.207

  < 65 years

51 (30.0%)

31 (23.5%)

 

  ≥ 65 years

119 (70.0%)

101 (76.5%)

 Gender

  

0.955

  Female

92 (54.1%)

71 (53.8%)

 

  Male

78 (45.9%)

61 (46.2%)

 Smoking

  

0.103

  No

21 (12.4%)

7 (5.3%)

 

  Yes

122 (71.8%)

100 (75.8%)

  NA

27 (15.8%)

25 (18.9%)

TCGA LUAD

 Stage

  

0.805

  I

114 (59.1%)

118 (57.8%)

 

  ≥ II

79 (40.9%)

86 (42.2%)

 Age

  

0.022*

  < 65 years

95 (47.5%)

7 (5.3%)

 

  ≥ 65 years

98 (49.0%)

100 (75.8%)

  NA

27 (15.8%)

25 (18.9%)

 Gender

  

0.337

  Female

104 (52.0%)

113 (56.8%)

 

  Male

96 (48.0%)

86 (43.2%)

 Smoking

  

0.056

  No

71 (35.5%)

53 (26.6%)

 

  Yes

129 (64.5%)

146 (73.4%)

  1. LUAD lung adenocarcinoma, TCGA The Cancer Genome Atlas, NA not available
  2. #Pearson’s chi-square test
  3. *Fisher’s exact test